A 12-month course of dupilumab improves otologic and sinonasal outcomes in adults with severe nasal polyps and eosinophilic ...

SAN DIEGO -- Tezepelumab (Tezspire) reduced nasal polyps and symptoms in severe chronic rhinosinusitis while also decreasing need for further treatments, the WAYPOINT trial showed. The monoclonal ...

An international collaboration of researchers, sponsored by GSK and working on behalf of the ANCHOR-1 and ANCHOR-2 trial investigators, conducted two Phase III clinical trials to evaluate depemokimab, ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Tezepelumab reduced the size of nasal polyps and the severity of nasal congestion in patients with severe, uncontrolled chronic rhinosinusitis with nasal polyps, in a placebo-controlled study.

Most people with chronic rhinosinusitis with nasal polyps (CRSwNP) are able to control their symptoms by using medicines that are sprayed into the nose or taken by mouth. But some people with this ...

A considerable proportion of patients with chronic rhinosinusitis with nasal polyps (CRSwNP) exhibit anxiety symptoms, according to a study published in the Journal of Inflammation Research. Pei-Wen ...

Chronic rhinosinusitis with nasal polyps is an inflammatory disorder of the nasal and paranasal sinus mucosa characterised by persistent mucosal oedema, polyp formation and variable airway obstruction ...

For severe chronic rhinosinusitis with nasal polyps, the novel monoclonal antibody stapokibart reduced symptoms and polyp size atop treatment with a daily intranasal corticosteroid. The polyp size ...

YARDLEY, Pa., March 15, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the ...

Please provide your email address to receive an email when new articles are posted on . The need for systemic corticosteroids fell by 88%, and the need for surgery fell by 98%. Nasal polyp and ...

THOUSAND OAKS, Calif., Oct. 17, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) approved TEZSPIRE® (tezepelumab-ekko) for the ...